绞股蓝颗粒对早期糖尿病肾病肾脏肾素-血管紧张素系统的影响  

Experimental study of Gold Theragran on rennin angiotensin system in diabetic nephropathy

作　　者：黄平[1] 钱康[2] 

机构地区：[1]浙江省中医院内分泌科,杭州310006 [2]杭州市第一人民医院中医科,杭州310006

出　　处：《中华中医药杂志》2010年第3期434-439,共6页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：浙江省中医药科技计划(No.2008CA009)~~

摘　　要：目的:为研究绞股蓝颗粒保护肾功能、抑制异常活化的糖尿病肾病肾脏肾素-血管紧张素系统的分子机制,并探讨其在早期糖尿病肾病发生、发展中的作用,为绞股蓝颗粒在临床应用于糖尿病肾病的防治提供理论和实验依据。方法:健康SD大鼠64只,体质量180-220g,雌雄各半,采用单侧肾切除加STZ注射法改良复制糖尿病肾病大鼠模型。随机取8只作为正常对照组(F组:灌胃同体积9%生理盐水),其余随机分为5组:绞股蓝颗粒高剂量组、绞股蓝颗粒中剂量组、绞股蓝颗粒低剂量组、缬沙坦组、模型对照组。每组分别观察血糖、血脂、肾功能、24h尿微量白蛋白、肾脏肥大指数、糖尿病肾病大鼠肾皮质血管紧张素转换酶活性、血浆及肾皮质血管紧张素Ⅱ浓度、以及Ⅰ型血管紧张素Ⅱ受体在肾组织的表达等。结果:①大鼠一般情况:各给药组大鼠的精神状况、反应、毛色与模型对照组比较有明显改善;②对糖代谢影响:除缬沙坦外(P>0.05),各给药组均有降低血糖代谢的作用;高、中剂量组与模型组比较有显著差异(P<0.01);③对脂代谢影响:高、中剂量组胆固醇、甘油三酯下降较为显著(P<0.05,P<0.01),高剂量组降脂作用第28d较第7d有明显优势(P<0.05);④对肾脏功能的影响:明显降低内生肌酐清除率,抑制肾脏肥大(P<0.05,P<0.01),高剂量组降尿素氮作用第28d较第7d有明显优势(P<0.05);⑤对肾脏肾素血管紧张素系统的影响:高、中剂量组能抑制肾脏局部血管紧张素活性转换酶活性(P<0.05,P<0.01),缬沙坦无明显抑制作用(P>0.05);高、中剂量组和缬沙坦降低血浆及肾组织血管紧张素Ⅱ浓度,减轻Ⅰ型血管紧张素Ⅱ受体在肾组织的过度表达(P<0.05,P<0.01)。结论:①绞股蓝颗粒对实验性DN大鼠有良好的治疗作用:调节血糖、血脂代谢,抑制实验性糖尿病肾病大鼠早期肾脏肥大和高滤过,减少尿蛋白的排出,保护肾功能;�Objective： To explore the molecular mechanism of Gold Theragran in the protection of renal function, and the inhibition of renal local rennin angiotensin （RA） system in the early diabetic nephropathy （DN）, and to provide the theoretical and experimental data for clinical application to prevent the DN. Methods： The experimental rats consisted of 64 healthy SD rats, average 180-220g, female and male both a half, rat model of DN was established by improved method of YANG Junwei＇s method of intraperitoneal injection of STZ after nephrectomy. 8 Rats was taken as normal group, the rest of them were randomly divided into 5 groups： high, middle and low dose groups of Gold Theragran, Valsartan group, model group. In each group, blood glucose, blood lipids, urine microalbumin per 24 hours, KW/BW, renal angiotensin converting enzyme, plasma and renal angiotensin Ⅱ, and its type 1 receptor were observsd and measured. Results： ①Rat＇s general status in each treatment group was improved compared with the DN model group.② The levels of serum glucose decreased in all treatment groups, especially the high-dose group and mid-dose group were significant （P〈0.01）, except of the Valsartan group （P〉0.05）.③The levels of abnormally high lever of TG, TC decreased in treatment groups, especially the high-dose group and mid-dose group were significant （P〈0.01, P〈0.05）, except of the Valsartan group （P〉0.05）. The high-dose group had further function to regulate the lipids in the 28th day than in the 7th day （P〈0.05）. ④All treatment groups can reduce the urine microalbumin, especially the high-dose and mid-dose group （P〈0.05, P〈0.01）. ⑤High-dose and mid-dose group can inhibit the activity of renal ACE, reduce the renal and plasma Ang II and the expression of its type 1 receptor （P〈0.01, P〈0.05）, the Valsartan group had no use on it （P〉0.05）. Conclusion： Firstly, Gold Theragran had a therapeutic effect of protecting the renal function on the experimental DN

关 键 词：绞股蓝 糖尿病肾病 肾素-血管紧张素系统 血管紧张素Ⅱ 血管紧张素转换酶 

分 类 号：R285.5[医药卫生—中药学]